Correction to Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events trial [J Am Heart Assoc. 2014;3: e001363 doi: 10.1161/JAHA.114.001363];Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The evaluation of cinacalcet hcl therapy to lower cardiovascular events (EVOLVE) trial

Journal of the American Heart Association

Volumn 3, Issue 6, 2014, Pages

  Wheeler, David C ^a   London, Gerard M ^b   Parfrey, Patrick S ^c   Block, Geoffrey A ^d   Correa Rotter, Ricardo ^e   Dehmel, Bastian ^f   Drüeke, Tilman B ^g   Floege, Jürgen ^h   Kubo, Yumi ^f   Mahaffey, Kenneth W ⁱ   Goodman, William G ^f   Moe, Sharon M ^j   Trotman, Marie Louise ^f   Abdalla, Safa ⁱ   Chertow, Glenn M ⁱ   Herzog, Charles A ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Hopital Manhes   (France)

^c Health Sciences Centre St John's   (Canada)

^d Denver Nephrology   (United States)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^f AMGEN INC   (United States)

^g UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

Atherosclerosis; Cardiovascular diseases; Heart failure; Kidney; Sudden death

Indexed keywords

CINACALCET; PLACEBO; CALCIMIMETIC AGENT; NAPHTHALENE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PERIPHERAL VASCULAR DISEASE; POST HOC ANALYSIS; PREMATURE MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; CLINICAL TRIAL; COMPLICATION; DEATH, SUDDEN, CARDIAC; DOUBLE BLIND PROCEDURE; HYPERPARATHYROIDISM, SECONDARY; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE, CHRONIC; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ATHEROSCLEROSIS; CALCIMIMETIC AGENTS; CINACALCET HYDROCHLORIDE; DEATH, SUDDEN, CARDIAC; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE, CHRONIC; MALE; NAPHTHALENES; RENAL DIALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939460510     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000570     Document Type: Erratum

References (28)

1. U.S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
2. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int. 2004;65:2380-2389.
3. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
4. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217-224.
5. Wheeler DC, Haynes R, Landray MJ, Baigent C. Cardiovascular aspects of kidney disease. In: Taal MW, Chertow GM, Marsden P, Skorecki K, Yu ASL, Brenner BM, eds. Brenner and Rector's The Kidney. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:2059-2080.
6. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-2192.
7. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
8. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
10. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2:898-905.
11. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482-2494.
12. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant. 2012;27:2872-2879.
13. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84:1065-1073.
14. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373-379.
15. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
16. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and metaanalysis. Ann Intern Med. 2012;157:251-262.
17. Natoli JL, Boer R, Nathanson BH, Miller RM, Chiroli S, Goodman WG, Belozeroff V. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis BMC Nephrol. 2013;14:88.
18. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519-530.
19. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109:697-711.
20. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John SM, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro O, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
21. Duprez D, Bauwens F, De Buyzere M, De Backer T, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL. Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension. J Hypertens Suppl. 1991;9:S116-S117.
22. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD. Left ventricular hypertrophy in end-stage renal disease. Nephron. 1988;48:107-115.
23. Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C, de Vernejoul P, Crosnier J. Effect of parathyroidectomy on left-ventricular function in hemodialysis patients. Lancet. 1980;1:112-114.
24. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327-1339.
25. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant. 2008;23:586-593.
26. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012;27:784-790.
27. Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA, Winkelmayer WC. Trends in the use and outcomes of implantable cardioverterdefibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis. 2011;58:409-417.
28. Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int. 2005;68:818-825.